Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
This article was originally published in The Tan Sheet
Executive Summary
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
You may also be interested in...
Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.
Rx-Only Pseudoephedrine Stalls As Meth Solution In Tennessee, Indiana
Tennessee’s meth lab seizures are up this year, but CHPA says that’s because more labs are uncovered through the state’s participation in the NPLEx stop-sale system. Rx-only bills have stalled in several states, including Indiana, where lawmakers passed a bill to cap PSE purchases at about 61 grams per year.
GAO Backs Prescription Pseudoephedrine Approach
Senator Feinstein says PSE products should be available only by prescription nationwide. A GAO report supports “an expansion of prescription-only laws in the fight to combat the serious epidemic of meth production,” she says.